Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Navigating Growth And Challenges, The Bright Future Of Oncology And Innovative Therapies
Merck & Co., Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$104.83 |
52 Week High | US$134.63 |
52 Week Low | US$99.80 |
Beta | 0.40 |
11 Month Change | -7.69% |
3 Month Change | -7.90% |
1 Year Change | 1.93% |
33 Year Change | 18.21% |
5 Year Change | 25.92% |
Change since IPO | 9,218.22% |
Recent News & Updates
Recent updates
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Oct 25Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)
Oct 15Merck Is At Support And Should Go Higher (Technical Analysis)
Oct 07Merck Appears Ready To Return To June Highs (Technical Analysis)
Sep 14Merck's Change To Profit Guidance Provides An Opportunity
Sep 01Merck: Buy This Bargain Before It's Gone
Aug 12Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 01Shareholder Returns
MRK | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.5% | -3.7% | 0.5% |
1Y | 1.9% | 22.6% | 36.8% |
Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned 22.6% over the past year.
Return vs Market: MRK underperformed the US Market which returned 36.8% over the past year.
Price Volatility
MRK volatility | |
---|---|
MRK Average Weekly Movement | 2.4% |
Pharmaceuticals Industry Average Movement | 9.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRK's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
MRK fundamental statistics | |
---|---|
Market cap | US$262.94b |
Earnings (TTM) | US$13.74b |
Revenue (TTM) | US$62.48b |
19.3x
P/E Ratio4.3x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRK income statement (TTM) | |
---|---|
Revenue | US$62.48b |
Cost of Revenue | US$15.13b |
Gross Profit | US$47.35b |
Other Expenses | US$33.62b |
Earnings | US$13.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
Earnings per share (EPS) | 5.42 |
Gross Margin | 75.79% |
Net Profit Margin | 21.98% |
Debt/Equity Ratio | 86.6% |
How did MRK perform over the long term?
See historical performance and comparison